Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares

Abstract:
AlphaRx Inc. , a leader in the development of Nanotechnology for Drug Delivery Platforms, announce that in order to meet TSX Venture Exchange listing requirements, its CEO, CFO, directors, consultants and employees plan to exercise stock options to purchase 3,300,000 shares of AlphaRx common stock. Michael Lee, President and CEO, will cancel 6,000,000 options granted to him in 2004 which carried a strike price of $0.15 a share and will exercise 1,862,228 warrants with a strike price of $0.10 a shares. Furthermore, certain company employees will voluntarily cancel 1,710,000 of their options at the same time to make the capital structure of the company more attractive for institutional investors. The company expects to complete these transactions on or before Dec 31, 2007.

AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares

MARKHAM, ON, Canada | Posted on December 28th, 2007

In conjunction of the above transactions, Michael Lee will purchase 6,000,000 company shares at a price of $0.15 a share under a private placement. The company expects to close this private placement on or before January 31, 2008.

The shares issued from the exercise of options, warrants and the private placement are subject to applicable hold periods and trading restrictions under the US Securities Act of 1933 and may only be offered, sold or otherwise transferred outside the US or inside the US in accordance with applicable exemptions from registration.

####

About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company also discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and neurodegenerative diseases.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.

For more information, please click here

Contacts:
168 Konrad Crescent
Suite 200, Markham
Ontario, Canada L3R 9T9
Phone: 905/479-3245
Fax: 416/352-6120
Email:

Douglas Dicconson
Director, Market & Business Development
Email:

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Bruker Announces Acquisition of Nanoindenting Leader Hysitron: Acquisition strengthens Brukerís leading position in nanoanalysis and nanomechanical materials characterization January 24th, 2017

New low-cost technique converts bulk alloys to oxide nanowires January 24th, 2017

News from Quorum: Experienced electron microscopist, David McCarthy, talks about working with Quorum and his use of their coaters and cryo-SEM preparation instrumentation January 24th, 2017

Tough aqua material for water purification: Decontamination of water with a robust and sustainable membrane assembled from 2 synergistically working components January 24th, 2017

Investments/IPO's/Splits

Harris & Harris Group Announces the Filing of Preliminary Proxy Materials Detailing Its Proposed Conversion From a BDC to a Registered Closed-End Fund January 24th, 2017

Harris & Harris Group Issues Reminder for Shareholder Update Call on January 10, 2017 January 10th, 2017

Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017

Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016

Nanomedicine

New, old science combine to make faster medical test: Nanoparticles and Faraday rotation allow faster diagnoses January 23rd, 2017

New research helps to meet the challenges of nanotechnology: Research helps to make the most of nanoscale catalytic effects for nanotechnology January 20th, 2017

Chemists Cook up New Nanomaterial and Imaging Method: Nanomaterials can store all kinds of things, including energy, drugs and other cargo January 19th, 2017

'5-D protein fingerprinting' could give insights into Alzheimer's, Parkinson's January 19th, 2017

Announcements

Bruker Announces Acquisition of Nanoindenting Leader Hysitron: Acquisition strengthens Brukerís leading position in nanoanalysis and nanomechanical materials characterization January 24th, 2017

New low-cost technique converts bulk alloys to oxide nanowires January 24th, 2017

News from Quorum: Experienced electron microscopist, David McCarthy, talks about working with Quorum and his use of their coaters and cryo-SEM preparation instrumentation January 24th, 2017

Tough aqua material for water purification: Decontamination of water with a robust and sustainable membrane assembled from 2 synergistically working components January 24th, 2017

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project